Astellas subsidiary Xyphos Biosciences has entered a research partnership and licence agreement with Kelonia Therapeutics aimed at developing new immuno-oncology therapeutics in an $875m deal.
The alliance will merge Xyphos’ ACCEL technology with Kelonia’s in vivo gene placement system to develop universal, off-the-shelf in vivo chimeric antigen receptor (CAR) T-cell therapies for up to two programmes.
Go deeper with GlobalData
Kelonia focuses on genetic medicine innovation and utilises its in vivo gene placement system to precisely deliver genetic material to the target cells within the patient’s body.
This system employs lentiviral particles for efficient delivery.
Xyphos’ ACCEL technology platform features the convertible CAR used on immune cells.
Xyphos will oversee the development and marketing of the products resulting from the joint research.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataKelonia is entitled to an upfront payment of $40m for the first programme.
If Xyphos opts for the second programme, an additional $35m will be paid to Kelonia.
The deal also includes potential milestones and contingency payments of $800m.
Kelonia also stands to gain from research and development (R&D) funding for its collaboration efforts in addition to tiered royalty payments on net product sales.
Astellas chief strategy officer Adam Pearson stated: “At Astellas, we have a strong commitment to developing novel treatments for patients with cancer and have positioned immuno-oncology as a primary focus of our R&D strategy.
“With iGPS, Kelonia has an elegant, cutting-edge in vivo delivery technology, and by combining with the ACCEL platform, we believe the collaboration will bring synergies between the two companies’ breakthrough research and will ultimately lead to expansion of Astellas’ portfolio and to delivery of innovative in vivo CAR-T cell therapies to cancer patients.”
In December 2023, Astellas Pharma and Elpiscience signed a research partnership and licence agreement for two new bispecific macrophage engagers, ES019 and another undisclosed programme, in a $1.7bn deal.
Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.
